Latest News

Thursday, January 19, 2017 | Pain & Headache, Research and Publications

Lower Vitamin D Levels in Men Linked to Increased Frequency of Headache

Low levels of vitamin D was associated with markedly higher risk of frequent headache in men, according to new findings published in Scientific Reports (Article number: 39697, 2017). Investi…

Read the full story

Thursday, January 19, 2017 | Epilepsy & Seizure Disorders, Personnel/Company News, Product Launches and Updates

Takeda and Ovid Strike Partnership to Develop Investigational Agent for Rare Pediatric Epilepsy

Takeda and Ovid Therapeutics are teaming up for the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel CH24H inhibitor, in rare pediatric epilepsies…

Read the full story

Wednesday, January 18, 2017 | Acquisitions and Mergers, Pain & Headache, Personnel/Company News

Lilly to Acquire Migraine Drug Maker CoLucid

Eli Lilly and Co. is set to acquire CoLucid Pharmaceuticals for $960 million. CoLucid is currently developing lasmiditan, a migraine medicine that could help patients with cardiovascular disease.…

Read the full story

Thursday, January 12, 2017 | Dementia & Cognitive Disorders, Research and Publications

High Levels of Aluminum Found in Brain Tissue of Individuals with Familial Alzheimer’s Disease

A British study has found extremely high levels of aluminum in the tissue of brains of individuals with familial Alzheimer’s disease. Using fluorescence microscopy to identify aluminum, investig…

Read the full story

Thursday, January 05, 2017 | Dementia & Cognitive Disorders, Phase 3/4 Trials, Research and Publications

Neuronix Reveals Data Suggesting Non-invasive TMS Device Improves Cognitive Performance in Alzheimer’s Disease

New findings suggest that an investigational device that combines transcranial magnetic stimulation (TMS) with cognitive training may improve cognitive performance in individuals with Alzheimer&r…

Read the full story

Wednesday, January 04, 2017 | Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech

Newly Published Phase 3 Data Boost Efficacy Profile of Ocrevus in Primary Progressive and Relapsing MS

As the FDA continues its review of the Biologics License Application (BLA) for Genentech’s Ocrevus (ocrelizumab), key phase 3 findings reviewing the agent’s safety and efficacy in relapsin…

Read the full story

Wednesday, December 21, 2016 | Dementia & Cognitive Disorders, Research and Publications

Phase 2 Data Finds Pimavanserin Effective and Well Tolerated in Patients with Alzheimer’s Disease Psychosis

Phase 2 Data Finds Pimavanserin Effective and Well Tolerated in Patients with Alzheimer’s Disease Psychosis Acadia Pharmaceuticals has unveiled positive top-line results from its Phase 2 expl…

Read the full story

Wednesday, December 21, 2016 | FDA Approval/Clearance, Neuromuscular & Immune Disorders, Genentech, Roche

FDA Extends Review of MS Agent Ocrevus to March 2017

The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application of Genentech’s investigational agent for the treatment of multiple sclero…

Read the full story

Friday, December 09, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

NeuroPace Unveils New Long-Term Data for Its RNS System

At the recent American Epilepsy Society Annual Meeting in Houston, NeuroPace shared new long-term data for its RNS System for the treatment of partial-onset seizure. The RNS System monitors and respon…

Read the full story

Thursday, December 08, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

Reflecting on New Phase 3 Epidiolex Data, GW Pharmaceuticals CEO Emphasizes Education About Cannabidiol

Greenwich Biosciences, a subsidiary of GW Pharmaceuticals, shared phase 3 data in poster presentations at the recent American Epilepsy Society Annual Meeting showing that it’s investigational ca…

Read the full story

Wednesday, December 07, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

AES 2016: Sunovion Launching Phase 4 Study of Aptiom Using Wearable Technology to Detect Seizure Activity

At the recent American Epilepsy Society Annual Meeting in Houston, Sunovion revealed that will soon initiate enrollment for a Phase 4 clinical study (Study 093-701) evaluating the use of the Embrace w…

Read the full story

Wednesday, December 07, 2016 | Epilepsy & Seizure Disorders, Research and Publications

AES 2016: Fenfluramine Found Effective for both Dravet Syndrome and LGS

New poster data from Zogenix presented at the recent American Epilepsy Society’s annual meeting in Houston paints an encouraging portrait of the company’s investigational fenfluramine agen…

Read the full story

Thursday, December 01, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Pfizer

Adjunctive Treatment with Lyrica Found to Reduce Seizure Frequency in Pediatric Epilepsy

New phase 3 results show that Lyrica (pregabalin, Pfizer) Capsules CV is an effective adjunctive therapy for patients with epilepsy between the ages of four and 16 years of age. Specifically, the resu…

Read the full story

Tuesday, November 29, 2016 | Movement Disorders, Research and Publications

Genetic Mutation Tied to Risk of Early Parkinson’s Disease

Aging appears to alter how genetic factors contribute to the development of Parkinson’s disease, according to new research that has identified a gene that may increase risk of early onset P…

Read the full story

Tuesday, November 22, 2016 | Dementia & Cognitive Disorders, Research and Publications

Saliva Test May Detect Alzheimer’s Disease

A new saliva test developed by Aurin Bitech could serve as a diagnostic marker for Alzheimer’s disease, according to new findings published the Journal of Alzheimers Disease. The test is based o…

Read the full story
Load More